Want to see DRMA full AI Analyst Report?
Top Page
Dermata Therapeutics
(NASDAQ:DRMA)
Select Model
Select Model
Rating:42Neutral
Price Target:
$1.00
▼(-24.24% Downside)
Action:Reiterated
Date:08/05/26
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, and significant cash burn) and bearish technical signals (price below key moving averages with negative MACD). Corporate events add some upside via a move toward commercialization, but valuation offers limited insight given negative earnings and no dividend yield.
Positive Factors
No debt on balance sheet
Absence of debt reduces financial risk and preserves capital allocation flexibility, allowing the company to prioritize product launch and marketing. Over 2–6 months this supports execution choices (equity financing, partnerships) without immediate leverage-driven solvency pressure.
Negative Factors
Pre-revenue with persistent losses
With no product revenue and sustained net losses, the company lacks internally generated earnings to fund growth. Until DTC sales materially scale, ongoing deficits will necessitate external capital, constraining strategic options and increasing execution risk over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
No debt on balance sheet
Absence of debt reduces financial risk and preserves capital allocation flexibility, allowing the company to prioritize product launch and marketing. Over 2–6 months this supports execution choices (equity financing, partnerships) without immediate leverage-driven solvency pressure.
Read all positive factors
Dermata Therapeutics (DRMA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.87M
Dividend YieldN/A
Average Volume (3M)249.42K
Price to Earnings (P/E)―
Beta (1Y)1.28
Revenue GrowthN/A
EPS Growth88.77%
CountryUS
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.39
Shares Outstanding4,022,143
10 Day Avg. Volume611,626
30 Day Avg. Volume249,418
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.35
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside203.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.21
Revenue Forecast (FY)$15.00M
Dermata Therapeutics Business Overview & Revenue Model
Company Description
Dermata Therapeutics, Inc. (DRMA) is a clinical-stage biotechnology company in the dermatology sector focused on developing and commercializing new treatments for skin diseases and aesthetic dermatology conditions. The company’s pipeline has inclu...
How the Company Makes Money
null...
Dermata Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -8.53M | -7.77M | -12.29M | 247.22K | -9.61M | -7.86M |
| Net Income | -8.37M | -7.56M | -12.29M | -7.79M | -9.61M | -7.90M |
Balance Sheet | ||||||
| Total Assets | 5.32M | 7.86M | 3.53M | 7.98M | 6.94M | 11.62M |
| Cash, Cash Equivalents and Short-Term Investments | 4.41M | 7.52M | 3.16M | 7.44M | 6.24M | 10.80M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.83M | 1.64M | 1.97M | 1.62M | 922.63K | 1.52M |
| Stockholders Equity | 3.49M | 6.22M | 1.56M | 6.36M | 6.02M | 10.11M |
Cash Flow | ||||||
| Free Cash Flow | -8.14M | -7.76B | -11.16M | -6.41M | -8.83M | -5.69M |
| Operating Cash Flow | -8.03M | -7.76B | -11.16M | -6.41M | -8.83M | -5.69M |
| Investing Cash Flow | -110.67K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 6.08M | 12.12B | 6.89M | 7.61M | 4.28M | 15.96M |
Dermata Therapeutics Technical Analysis
Positive
1.32
Price Trends
1.26
Positive
1.27
Positive
1.73
Negative
Market Momentum
0.02
Negative
61.48
Neutral
82.76
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DRMA, the sentiment is Positive. The current price of 1.32 is above the 20-day moving average (MA) of 1.23, above the 50-day MA of 1.26, and below the 200-day MA of 1.73, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 61.48 is Neutral, neither overbought nor oversold. The STOCH value of 82.76 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DRMA.
Dermata Therapeutics Risk Analysis
Dermata Therapeutics disclosed 87 risk factors in its most recent earnings report. Dermata Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Dermata Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
DRMA
Dermata Therapeutics
1.46
-4.46
-75.34%
REVB
Revelation Biosciences
1.05
-9.79
-90.32%
CERO
CERo Therapeutics Holdings
0.01
-8.79
-99.88%
PBM
Psyence Biomedical
3.48
-17.15
-83.13%
AZTR
Azitra Inc
0.14
-0.83
-85.60%
Dermata Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Dermata Therapeutics Launches Tome Foundational Skincare Line
Positive
Aug 5, 2026
On August 5, 2026, Dermata Therapeutics, Inc. announced plans to launch its first commercial product, Tome Foundational Treatment, marking a strategic move into revenue-generating consumer skincare. The regimen-based set, comprising four once-week...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingShareholder Meetings
Dermata Therapeutics Shareholders Approve Equity Plan and Directors
Positive
May 27, 2026
On May 27, 2026, Dermata Therapeutics held its 2026 Annual Meeting of Stockholders, where shareholders approved an amendment to the company’s 2021 Omnibus Equity Incentive Plan, increasing the shares available for issuance to 402,214 and rea...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.